Lineage Cell Therapeutics
LCTX
LCTX
108 hedge funds and large institutions have $56.4M invested in Lineage Cell Therapeutics in 2019 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
0.79% less ownership
Funds ownership: 43.08% → 42.29% (-0.79%)
11% less capital invested
Capital invested by funds: $63.2M → $56.4M (-$6.78M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Holders
108
Holding in Top 10
3
Calls
–
Puts
$2K
Top Buyers
| 1 | +$163K | |
| 2 | +$142K | |
| 3 | +$117K | |
| 4 |
Morgan Stanley
New York
|
+$106K |
| 5 |
JPMorgan Chase & Co
New York
|
+$95.3K |
Top Sellers
| 1 | -$1.15M | |
| 2 | -$516K | |
| 3 | -$153K | |
| 4 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
-$151K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$97.4K |